Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

OptimizeRx (OPRX) Gains from Investment Securities: 2017-2025

Historic Gains from Investment Securities for OptimizeRx (OPRX) over the last 9 years, with Q2 2025 value amounting to $5000.0.

  • OptimizeRx's Gains from Investment Securities fell 9879.52% to $5000.0 in Q2 2025 from the same period last year, while for Jun 2025 it was $503000.0, marking a year-over-year decrease of 4164.73%. This contributed to the annual value of $1.8 million for FY2024, which is 1869.95% up from last year.
  • As of Q2 2025, OptimizeRx's Gains from Investment Securities stood at $5000.0, which was down 9879.52% from $87000.0 recorded in Q1 2025.
  • Over the past 5 years, OptimizeRx's Gains from Investment Securities peaked at $8.5 million during Q1 2022, and registered a low of -$51.1 million during Q4 2021.
  • Its 5-year average for Gains from Investment Securities is -$2.6 million, with a median of $113500.0 in 2024.
  • Data for OptimizeRx's Gains from Investment Securities shows a peak YoY increase of 206551.58% (in 2022) and a maximum YoY decrease of 22800113.77% (in 2022) over the last 5 years.
  • Over the past 5 years, OptimizeRx's Gains from Investment Securities (Quarter) stood at -$51.1 million in 2021, then skyrocketed by 102.56% to $1.3 million in 2022, then tumbled by 87.22% to $167000.0 in 2023, then skyrocketed by 94.01% to $324000.0 in 2024, then tumbled by 98.46% to $5000.0 in 2025.
  • Its Gains from Investment Securities stands at $5000.0 for Q2 2025, versus $87000.0 for Q1 2025 and $324000.0 for Q4 2024.